DR. JEANNA WELBORN M.D.
Prescription History 1104808849
Internal Medicine - Hematology & Oncology in Sacramento, CA

NPI Status: Active since November 17, 2005

Contact Information

2279 45TH STREET
SACRAMENTO, CA
ZIP 95817
Phone: (916) 734-5959
Fax: (916) 703-5265

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. JEANNA WELBORN M.D., an active Hematology & Oncology specialist practicing in Sacramento, CA. Our medical registry currently tracks 16 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 412 documented patient claims. Among these therapy options, the most frequently utilized medication is Hydroxyurea, which accounts for 80 claims alone.


Acyclovir

Generic Formulation: AcyclovirSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 22
30-Day Fills 46.0
Days Supply 1,380
CA State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills38.5
Peer Average Days Supply971
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $410.70 across this reporting matrix range.

Provider Avg Cost Per Claim

$18.67

State Avg Cost Per Claim

$26.52

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes.

Therapeutic Applications

Acyclovir is used to treat infections caused by certain types of viruses. It treats cold sores around the mouth (caused by herpes simplex), shingles (caused by herpes zoster), and chickenpox. This medication is also used to treat outbreaks of genital herpes. In people with frequent outbreaks, acyclovir is used to help reduce the number of future episodes. Acyclovir is an antiviral drug. However, it is not a cure for these infections. The viruses that cause these infections continue to live in the body even between outbreaks. Acyclovir decreases the severity and length of these outbreaks. It helps the sores heal faster, keeps new sores from forming, and decreases pain/itching. This medication may also help reduce how long pain remains after the sores heal. In addition, in people with a weakened immune system, acyclovir can decrease the risk of the virus spreading to other parts of the body and causing serious infections.

Allopurinol

Generic Formulation: AllopurinolSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 314
CA State Average Benchmarks
Peer Average Claims44.0
Peer Average 30-Day Fills110.3
Peer Average Days Supply3,283
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 75.0% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $68.36 across this reporting matrix range.

Provider Avg Cost Per Claim

$6.21

State Avg Cost Per Claim

$15.90

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A XANTHINE OXIDASE inhibitor that decreases URIC ACID production. It also acts as an antimetabolite on some simpler organisms.

Therapeutic Applications

Allopurinol is used to treat gout and certain types of kidney stones. It is also used to prevent increased uric acid levels in patients receiving cancer chemotherapy. These patients can have increased uric acid levels due to release of uric acid from the dying cancer cells. Allopurinol works by reducing the amount of uric acid made by the body. Increased uric acid levels can cause gout and kidney problems.

Anagrelide Hcl

Generic Formulation: Anagrelide HclSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 18
30-Day Fills 42.0
Days Supply 1,260
CA State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills27.5
Peer Average Days Supply815
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $8,318.88 across this reporting matrix range.

Provider Avg Cost Per Claim

$462.16

State Avg Cost Per Claim

$421.42

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Anagrelide is used to treat a certain blood disorder (thrombocythemia), which is caused by your bone marrow making too many platelets. Platelets are a blood cell that the body uses to form blood clots. Too many platelets can cause problems with your circulation, including unwanted blood clots and bleeding problems. This drug reduces the number of platelets in the bloodstream by blocking their production.

Bosulif

Generic Formulation: BosutinibSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
CA State Average Benchmarks
Peer Average Claims16.0
Peer Average 30-Day Fills17.0
Peer Average Days Supply507
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $222,468.84 across this reporting matrix range.

Provider Avg Cost Per Claim

$18,539.07

State Avg Cost Per Claim

$13,887.58

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Bosutinib is used to treat a certain type of blood cancer (chronic myelogenous leukemia-CML). It works by slowing or stopping the growth of cancer cells.

Brukinsa

Generic Formulation: ZanubrutinibSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 14
30-Day Fills 14.0
Days Supply 420
CA State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills24.4
Peer Average Days Supply728
Conservative Utilization

This provider writes prescriptions for this formulation 41.7% less frequently than the standard regional baseline metric for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $211,349.14 across this reporting matrix range.

Provider Avg Cost Per Claim

$15,096.37

State Avg Cost Per Claim

$11,990.55

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain cancers (mantle cell lymphoma, marginal zone lymphoma, Waldenstrom's macroglobulinemia). Zanubrutinib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells.

Calquence

Generic Formulation: Acalabrutinib MaleateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 31
30-Day Fills 31.0
Days Supply 930
CA State Average Benchmarks
Peer Average Claims16.0
Peer Average 30-Day Fills16.6
Peer Average Days Supply495
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 93.8% higher than the standard regional baseline profile for CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $458,812.57 across this reporting matrix range.

Provider Avg Cost Per Claim

$14,800.41

State Avg Cost Per Claim

$14,069.64

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain types of cancer (such as mantle cell lymphoma, small lymphocytic lymphoma - SLL, chronic lymphocytic leukemia - CLL). Acalabrutinib works by slowing or stopping the growth of cancer cells. It belongs to a class of drugs known as kinase inhibitors.

Dexamethasone

Generic Formulation: DexamethasoneSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 19
30-Day Fills 24.4
Days Supply 650
CA State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills36.0
Peer Average Days Supply559
Conservative Utilization

This provider writes prescriptions for this formulation 40.6% less frequently than the standard regional baseline metric for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $371.20 across this reporting matrix range.

Provider Avg Cost Per Claim

$19.54

State Avg Cost Per Claim

$19.76

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An anti-inflammatory 9-fluoro-glucocorticoid.

Therapeutic Applications

Dexamethasone is used to treat conditions such as arthritis, blood/hormone disorders, allergic reactions, skin diseases, eye problems, breathing problems, bowel disorders, cancer, and immune system disorders. It is also used as a test for an adrenal gland disorder (Cushing's syndrome). Dexamethasone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Hydroxyurea

Generic Formulation: HydroxyureaSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 80
30-Day Fills 171.6
Days Supply 5,047
CA State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills69.5
Peer Average Days Supply2,062
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 142.4% higher than the standard regional baseline profile for CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,136.98 across this reporting matrix range.

Provider Avg Cost Per Claim

$39.21

State Avg Cost Per Claim

$42.36

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.

Therapeutic Applications

This medication is used by people with sickle cell anemia to reduce the number of painful crises caused by the disease and to reduce the need for blood transfusions. Some brands are also used to treat certain types of cancer (such as chronic myelogenous leukemia, squamous cell carcinomas).

Imatinib Mesylate

Generic Formulation: Imatinib MesylateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 16
30-Day Fills 16.0
Days Supply 480
CA State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills24.4
Peer Average Days Supply728
Conservative Utilization

This provider writes prescriptions for this formulation 27.3% less frequently than the standard regional baseline metric for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $20,688.64 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,293.04

State Avg Cost Per Claim

$1,586.92

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A tyrosine kinase inhibitor and ANTINEOPLASTIC AGENT that inhibits the BCR-ABL kinase created by chromosome rearrangements in CHRONIC MYELOID LEUKEMIA and ACUTE LYMPHOBLASTIC LEUKEMIA, as well as PDG-derived tyrosine kinases that are overexpressed in gastrointestinal stromal tumors.

Therapeutic Applications

This medication is used to treat certain types of cancer (such as acute lymphoblastic leukemia, chronic myeloid leukemia, gastrointestinal stromal tumors, and myelodysplastic/myeloproliferative diseases). It works by slowing or stopping the growth of cancer cells. Imatinib may also be used to treat certain immune system disorders (such as aggressive systemic mastocytosis, hypereosinophilic syndrome).

Imbruvica

Generic Formulation: IbrutinibSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 34
30-Day Fills 34.0
Days Supply 952
CA State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills29.0
Peer Average Days Supply826
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $556,612.79 across this reporting matrix range.

Provider Avg Cost Per Claim

$16,370.96

State Avg Cost Per Claim

$15,007.19

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain cancers (such as mantle cell or marginal zone lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenstrom's macroglobulinemia). Ibrutinib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells. Ibrutinib is also used to treat a certain problem that may occur after a stem cell transplant (chronic graft versus host disease). It works by weakening your body's defense system (immune system).

Lenalidomide

Generic Formulation: LenalidomideSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 16
30-Day Fills 16.0
Days Supply 448
CA State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills26.3
Peer Average Days Supply700
Conservative Utilization

This provider writes prescriptions for this formulation 38.5% less frequently than the standard regional baseline metric for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $197,665.67 across this reporting matrix range.

Provider Avg Cost Per Claim

$12,354.10

State Avg Cost Per Claim

$12,446.95

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A phthalimide and piperidone derivative that has immunomodulatory and antiangiogenic properties. It is used for the treatment of transfusion-dependent anemia in MYELODYSPLASTIC SYNDROMES, and for the treatment of MULTIPLE MYELOMA, and relapsed or refractory MANTLE CELL LYMPHOMA.

Therapeutic Applications

Lenalidomide is used to treat various types of cancers. It works by slowing or stopping the growth of cancer cells. It is also used to treat anemia in patients with certain blood/bone marrow disorders (myelodysplastic syndromes-MDS). Lenalidomide may lessen the need for blood transfusions. Lenalidomide is not recommended for the treatment of a certain type of cancer (chronic lymphocytic leukemia) because of the increased risk of serious heart-related side effects and death. If you have this type of cancer, talk to your doctor about the risks of using this medication.

Lorazepam

Generic Formulation: LorazepamSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 14
30-Day Fills 14.0
Days Supply 140
CA State Average Benchmarks
Peer Average Claims45.0
Peer Average 30-Day Fills48.5
Peer Average Days Supply1,223
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 68.9% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $26.50 across this reporting matrix range.

Provider Avg Cost Per Claim

$1.89

State Avg Cost Per Claim

$7.40

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A benzodiazepine used as an anti-anxiety agent with few side effects. It also has hypnotic, anticonvulsant, and considerable sedative properties and has been proposed as a preanesthetic agent.

Therapeutic Applications

This medication is used to treat serious seizures that do not stop (status epilepticus). It is also used before surgeries or procedures to cause drowsiness, decrease anxiety, and cause forgetfulness about the procedure or surgery. Lorazepam belongs to a class of medications called benzodiazepines, which produce a calming effect on the brain and nerves (central nervous system). It is thought to work by increasing the effect of a certain natural chemical (GABA) in the brain.

Omeprazole

Generic Formulation: OmeprazoleSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 16
30-Day Fills 24.0
Days Supply 702
CA State Average Benchmarks
Peer Average Claims80.0
Peer Average 30-Day Fills174.0
Peer Average Days Supply5,169
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 80.0% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $91.39 across this reporting matrix range.

Provider Avg Cost Per Claim

$5.71

State Avg Cost Per Claim

$13.72

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.

Therapeutic Applications

Omeprazole is used to treat certain stomach and esophagus problems (such as acid reflux, ulcers). It works by decreasing the amount of acid your stomach makes. It relieves symptoms such as heartburn, difficulty swallowing, and cough. This medication helps heal acid damage to the stomach and esophagus, helps prevent ulcers, and may help prevent cancer of the esophagus. Omeprazole belongs to a class of drugs known as proton pump inhibitors (PPIs). If you are self-treating with this medication, over-the-counter omeprazole products are used to treat frequent heartburn (occurring 2 or more days a week). Since it may take 1 to 4 days to have full effect, these products do not relieve heartburn right away. For over-the-counter products, carefully read the package instructions to make sure the product is right for you. Check the ingredients on the label even if you have used the product before. The manufacturer may have changed the ingredients. Also, products with similar brand names may contain different ingredients meant for different purposes. Taking the wrong product could harm you.

Procrit

Generic Formulation: Epoetin AlfaSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 23
30-Day Fills 23.4
Days Supply 658
CA State Average Benchmarks
Peer Average Claims38.0
Peer Average 30-Day Fills42.1
Peer Average Days Supply1,095
Conservative Utilization

This provider writes prescriptions for this formulation 39.5% less frequently than the standard regional baseline metric for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $120,522.25 across this reporting matrix range.

Provider Avg Cost Per Claim

$5,240.10

State Avg Cost Per Claim

$1,614.25

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A recombinant glycosylated form of erythropoietin which stimulates the differentiation and proliferation of erythroid precursors. It is used for the treatment of ANEMIA associated with CHRONIC RENAL FAILURE in dialysis and predialysis patients.

Therapeutic Applications

This medication is used to treat anemia (low red blood cell count) in people with long-term serious kidney disease (chronic kidney failure), people receiving zidovudine to treat HIV, and people receiving chemotherapy for some types of cancer (cancer that does not involve the bone marrow or blood cells). It may also be used in anemic patients to reduce the need for blood transfusions before certain planned surgeries that have a high risk of blood loss (usually given with an anticoagulant/blood thinner medication such as warfarin to lower the risk of serious blood clots). Epoetin alfa works by signaling the bone marrow to make more red blood cells. This medication is very similar to the natural substance in your body (erythropoietin) that prevents anemia. This monograph is about the following epoetin alfa products: epoetin alfa and epoetin alfa-epbx.

Revlimid

Generic Formulation: LenalidomideSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 40
30-Day Fills 40.0
Days Supply 1,120
CA State Average Benchmarks
Peer Average Claims37.0
Peer Average 30-Day Fills37.7
Peer Average Days Supply1,011
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $569,865.29 across this reporting matrix range.

Provider Avg Cost Per Claim

$14,246.63

State Avg Cost Per Claim

$18,322.70

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A phthalimide and piperidone derivative that has immunomodulatory and antiangiogenic properties. It is used for the treatment of transfusion-dependent anemia in MYELODYSPLASTIC SYNDROMES, and for the treatment of MULTIPLE MYELOMA, and relapsed or refractory MANTLE CELL LYMPHOMA.

Therapeutic Applications

Lenalidomide is used to treat various types of cancers. It works by slowing or stopping the growth of cancer cells. It is also used to treat anemia in patients with certain blood/bone marrow disorders (myelodysplastic syndromes-MDS). Lenalidomide may lessen the need for blood transfusions. Lenalidomide is not recommended for the treatment of a certain type of cancer (chronic lymphocytic leukemia) because of the increased risk of serious heart-related side effects and death. If you have this type of cancer, talk to your doctor about the risks of using this medication.

Sprycel

Generic Formulation: DasatinibSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 46
30-Day Fills 46.0
Days Supply 1,380
CA State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills19.0
Peer Average Days Supply566
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 155.6% higher than the standard regional baseline profile for CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $561,565.87 across this reporting matrix range.

Provider Avg Cost Per Claim

$12,207.95

State Avg Cost Per Claim

$12,035.74

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pyrimidine and thiazole derived ANTINEOPLASTIC AGENT and PROTEIN KINASE INHIBITOR of BCR-ABL KINASE. It is used in the treatment of patients with CHRONIC MYELOID LEUKEMIA who are resistant or intolerant to IMATINIB.

Therapeutic Applications

This medication is used to treat certain types of cancer (chronic myeloid leukemia-CML, acute lymphoblastic leukemia-ALL). It works by slowing or stopping the growth of cancer cells.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. JEANNA WELBORN M.D. provides transparency into local medical care patterns within Sacramento, CA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Hematology & Oncology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.